Medscape

GLP-1 RAs Associated With Reduced Colorectal Cancer Risk in Patients With Type 2 Diabetes

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for colorectal cancer (CRC) in patients with type 2 diabetes, with and without overweight or obesity, according ...
Monthly Prescribing Reference

ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer

The GLP-1 RA cohort had significantly lower odds of developing early-onset colorectal cancer (0.4 vs 0.7%) vs the no GLP-1 RA cohort. HealthDay News — Glucagon-like peptide-1 receptor agonists (GLP-1 ...
Nasdaq

Cardiff Oncology Completes Patient Enrollment in Phase 2 CRDF-004 Trial for RAS-Mutated Metastatic Colorectal Cancer, Additional Data Expected in 1H 2025

Cardiff Oncology completed patient enrollment in the Phase 2 CRDF-004 trial for RAS-mutated mCRC, with data expected in 2025. Cardiff Oncology, Inc. announced the completion of patient enrollment in ...

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor ...
Seeking Alpha

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...